Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.

Expert opinion on drug metabolism & toxicology - 1 Apr 2017

Brieva Teresa, Rivero Antonio, Rivero-Juarez Antonio

Abstract excerpt

INTRODUCTION: The fixed-dose combination therapy of sofosbuvir (SOF) plus velpatasvir (VEL) is the first pangenotypic, direct-acting antiviral (DAA), single-treatment regimen (STR) for the treatment of hepatitis C virus (HCV) infection to be commercialized. It is approved for the treatment of HCV genotypes 1, 2, 3, 4, 5, and 6. Following approval in 2016, new pharmacokinetic and pharmacodynamic data were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carbamates

Share to Drug Combinations

Share to Hepacivirus

Share to Hepatitis C

Share to Heterocyclic Compounds, 4 or More Rings

Share to Sofosbuvir

Source

Identifiers

PMID: 28165830
DOI: 10.1080/17425255.2017.1292253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.PMID 28165830Read ↗

Sofosbuvir and velpatasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.Semantic proximity Read ↗

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Semantic proximity Read ↗

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Real-world efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in treatment-naive and treatment-experienced chronic hepatitis c patients: a single-center study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.